Clinical trial · Interventional
Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.
Lidocaine Infusion With Enhanced Recovery Program for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The whole world now is directed to implement strategies that enhance the patient's quality of life and prevent tumor relapse. Enhanced recovery after pancreatic surgery (ERAPS) program was found to improve the quality of life as it is an evidence-based protocol designed to standardize and optimize perioperative medical care in order to reduce surgical trauma, perioperative physiological stress, organ dysfunction, reduction of clinical complications, length of hospital stay and the health costs together with increase of patient satisfaction. lidocaine; it is an amide local anaesthetic Recently its use as intravenous perioperative infusion for abdominal cancer surgeries is encouraging, as it significantly reduces postoperative pain, opioid consumption and nausea and vomiting. it also promotes gastrointestinal function recovery, and shortens the postoperative hospital stay. In addition, lidocaine in particular can act directly and indirectly on pancreatic cancer cells and the tumor microenvironment. The investigators suggest that IV lidocaine infusion in combination with ERAPS protocol may achieve better postoperative outcomes after pancreatic surgery for cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Pancreas | Malignant Pancreatic Neoplasm | ALIAS | 0.90 |
| ERAS | — | UNRESOLVED | — |
| Lidocaine | — | UNRESOLVED | — |
| Natural Killer Cell Cytokine Production | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine IV | Drug | — | UNRESOLVED |
| saline IV | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- infusion of intraoperative lidocaine to patients undergoing whipple surgery
- description
- lidocaine 1.5mg/kg infused as bolus, then 2mg/kg/hr through the operation
- interventionNames
- Drug: Lidocaine IV
- type
- EXPERIMENTAL
- label
- saline infusion of same volume of lidocaine
- description
- same amount of normal saline infused as bolus and infusion
- interventionNames
- Other: saline IV
Primary outcomes (1)
- measure
- Post-operative nociceptive pain assessment.
- timeFrame
- 24 hours postoperative
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 30-70 years 2. Both sex. 3. American society of anesthesiology (ASA) physical status class II;III. 4. Resectable pancreatic tumors. Exclusion Criteria: 1. Patients with history of sensitivity to lidocaine, 2. Diabetic patients. 3. Body weight loss \> 15%. 4. Opioid tolerant patient or patient receiving nonsteroidal anti-inflammatory drugs within 1 week of surgery or antiarrythmic drugs. 5. Cognitive dysfunction. 6. Any history of antitumor treatments or chemotherapy before surgery 7. Any contraindication for neuraxial anaesthesia.
References
Publications (0)
Data not yet available